We are live on ! Find out more
OC

Oppenheimer & Co Portfolio holdings

AUM $8.21B
1-Year Est. Return 28.81%
This Fund
S&P 500
This Quarter Est. Return
+2.6%
1 Year Est. Return
+28.81%
3 Year Est. Return
+92.54%
5 Year Est. Return
+114.67%
10 Year Est. Return
+429.8%
AUM
$3.34B
AUM Growth
+$209M
Cap. Flow
+$157M
Cap. Flow %
4.72%
Top 10 Hldgs %
12.01%
Holding
1,564
New
189
Increased
576
Reduced
529
Closed
163

Sector Composition

Rank Sector Weight
1 Energy 11.94%
2 Healthcare 10.62%
3 Industrials 9.8%
4 Technology 9.43%
5 Financials 9.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MRO
126
DELISTED
Marathon Oil Corporation
MRO
$6.44M 0.19%
181,407
+52,653
+41% +$1.77M
NKY
127
DELISTED
PRECIDIAN INVESTMENTS MAXIS NIKKEI 225 INDEX
NKY
$6.36M 0.19%
371,830
-39,869
-10% -$689K
CELG
128
DELISTED
Celgene Corp
CELG
$6.31M 0.19%
90,448
+30,946
+52% +$2.45M
DXJ icon
129
WisdomTree Japan Hedged Equity Fund
DXJ
$7.13B
$6.31M 0.19%
133,307
+48,748
+58% +$2.32M
ESRX
130
DELISTED
Express Scripts Holding Company
ESRX
$6.31M 0.19%
84,008
-733
-0.9% -$54.9K
AGN
131
DELISTED
Allergan plc
AGN
$6.29M 0.19%
30,547
-493
-2% -$97.7K
WPX
132
DELISTED
WPX Energy, Inc.
WPX
$6.19M 0.19%
343,310
+32,300
+10% +$596K
AAL icon
133
American Airlines Group
AAL
$10.2B
$6.18M 0.19%
168,865
+103,130
+157% +$3.51M
PSX icon
134
Phillips 66
PSX
$84.4B
$6.15M 0.18%
79,831
-23,137
-22% -$1.76M
AGN
135
DELISTED
Allergan Inc
AGN
$6.1M 0.18%
49,174
-1,048
-2% -$128K
LMT icon
136
Lockheed Martin
LMT
$132B
$6.08M 0.18%
37,216
+16,098
+76% +$2.53M
AMT icon
137
American Tower
AMT
$81.3B
$6.04M 0.18%
73,835
-1,730
-2% -$141K
ABT icon
138
Abbott
ABT
$183B
$6.04M 0.18%
156,931
-10,489
-6% -$404K
XLF icon
139
State Street Financial Select Sector SPDR ETF
XLF
$56.8B
$6.04M 0.18%
307,770
+46,534
+18% +$888K
FIG
140
DELISTED
Fortress Investment Group Llc
FIG
$5.98M 0.18%
807,982
+165,869
+26% +$1.38M
IBB icon
141
iShares Biotechnology ETF
IBB
$9.52B
$5.97M 0.18%
75,834
+1,149
+2% +$95.7K
DVN icon
142
Devon Energy
DVN
$50.9B
$5.92M 0.18%
88,441
-45,286
-34% -$2.81M
BAX icon
143
Baxter International
BAX
$13.8B
$5.82M 0.17%
145,470
-9,016
-6% -$337K
EQNR icon
144
Equinor
EQNR
$96.8B
$5.59M 0.17%
198,060
-3,134
-2% -$80.8K
USB icon
145
US Bancorp
USB
$98B
$5.57M 0.17%
129,857
-3,318
-2% -$136K
EEM icon
146
iShares MSCI Emerging Markets ETF
EEM
$28.6B
$5.55M 0.17%
135,259
-27,442
-17% -$1.08M
AZZ icon
147
AZZ Inc
AZZ
$4.36B
$5.51M 0.17%
123,250
CBI
148
DELISTED
Chicago Bridge & Iron Nv
CBI
$5.42M 0.16%
62,189
+1,469
+2% +$119K
UNP icon
149
Union Pacific
UNP
$172B
$5.39M 0.16%
57,498
+208
+0.4% +$18.5K
BKLN icon
150
Invesco Senior Loan ETF
BKLN
$6.97B
$5.33M 0.16%
214,903
+49,875
+30% +$1.24M

Similar funds

Oppenheimer & Co's Q1 2014 Portfolio in Review

As of Q1 2014, Oppenheimer & Co held 1,564 positions worth $3.34B, up 6.7% from $3.13B the previous quarter. Its ten largest holdings account for 12% of the portfolio.

Oppenheimer & Co deployed $157M of net new capital in Q1 2014, opening 189 new positions and adding to 576 existing holdings. Its largest new stake was Vanguard Morningstar Total Stock Market ETF: 169,083 shares worth $16.5M.

By sector, the portfolio is most concentrated in Energy at 12% of assets, down from 12% a quarter earlier, followed by Healthcare and Industrials.

On the sell side, the largest reduction was Vanguard Dividend Appreciation ETF, an estimated $7.79M trimmed.

  • Oppenheimer & Co's largest Q1 2014 buy was Vanguard Morningstar Total Stock Market ETF: 169,083 shares worth $16.5M.
  • Oppenheimer & Co added most to Monsanto Co in Q1 2014, an estimated $30M increase.
  • Oppenheimer & Co's biggest Q1 2014 reduction was Vanguard Dividend Appreciation ETF, cutting an estimated $7.79M.
  • Oppenheimer & Co fully exited TetraLogic Pharmaceuticals Corporation in Q1 2014, selling an estimated $10.2M.
  • Oppenheimer & Co's ten largest holdings make up 12% of its $3.34B portfolio in Q1 2014.
  • Oppenheimer & Co opened 189 new positions and closed 163 in Q1 2014.
  • Oppenheimer & Co's portfolio value rose 6.7% quarter-over-quarter to $3.34B.

Based on Oppenheimer & Co's 13F filing for Q1 2014, filed 9 May 2014.